Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19075741 | 0.89 | MEN1 (0.52) | HTTMEN1KMT2AALDH1A1POLB | |
| SCHEMBL17428532 | 0.78 | HTT (0.63) | HTTMEN1KMT2AALDH1A1POLB | |
| SCHEMBL17428526 | 0.78 | HTT (0.60) | HTTMEN1KMT2AALDH1A1POLB | |
| SCHEMBL19075732 | 0.76 | KMT2A (0.55) | HTTMEN1KMT2AALDH1A1POLB | |
| SCHEMBL25680296 | 0.74 | HPGD (0.66) | HTTMEN1KMT2AALDH1A1POLB | |
| SCHEMBL242779 | 0.72 | KMT2A (0.55) | HTTMEN1KMT2AALDH1A1POLB | |
| SCHEMBL28931981 | 0.70 | ALDH1A1 (0.67) | HTTMEN1KMT2AALDH1A1POLB | |
| SCHEMBL30636140 | 0.70 | ALDH1A1 (0.67) | HTTMEN1KMT2AALDH1A1POLB | |
| SCHEMBL28677555 | 0.67 | KMT2A (0.72) | HTTMEN1KMT2AALDH1A1POLB | |
| SCHEMBL28691090 | 0.67 | NPC1 (0.60) | HTTMEN1KMT2AALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | HTT 1368/4885MEN1 1465/4885KMT2A 1836/4885 |
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | HTT 1368/4885MEN1 1465/4885KMT2A 1836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.